Search / Trial NCT00000955

Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of June 13, 2024

Completed

Keywords

Tuberculosis Immunologic Tests Tuberculin Tuberculin Test Aids Related Opportunistic Infections Injections, Intradermal Acquired Immunodeficiency Syndrome Aids Related Complex Hypersensitivity, Delayed

Description

The accuracy of skin testing to detect Mycobacterium tuberculosis (MTb) infection is dependent upon the host's ability to mount a delayed-type hypersensitivity (DTH) reaction; however, the DTH response may be impaired or absent in patients with impaired cell-mediated immunity, a classic characteristic of HIV infection. Patients in whom immunity is diminished, but not absent, may test negative the first time a purified protein derivative skin test for MTb is administered, but if the same skin test is repeated, a positive DTH response may then be elicited. This occurrence is known as the "boo...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • HIV infection.
  • Negative PPD skin test within previous 7-28 days.
  • Exclusion Criteria
  • Concurrent Medication:
  • Excluded:
  • Steroids.
  • Live viral vaccines.
  • Antihistamines.
  • Chemoprophylaxis or chemotherapy for suspected or confirmed tuberculosis.
  • Patients with the following prior conditions are excluded:
  • History of documented positive PPD skin test.
  • History of tuberculosis or who are presently receiving chemoprophylaxis or chemotherapy for suspected or confirmed tuberculosis.
  • History of sensitivity to tuberculin or components of PPD.
  • Prior Medication:
  • Excluded:
  • Live viral vaccine within the past 4 weeks.
  • Steroid therapy within the past 4 weeks.
  • Antihistamines within the past week.
  • Chemoprophylaxis or chemotherapy for suspected or confirmed tuberculosis.

Attachments

readout_NCT00000955_2024-06-13.pdf

4.5 MB

NCT00000955_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

New Haven, Connecticut, United States

Wilmington, Delaware, United States

Washington, District Of Columbia, United States

Chicago, Illinois, United States

New Orleans, Louisiana, United States

Detroit, Michigan, United States

Detroit, Michigan, United States

Newark, New Jersey, United States

Bronx, New York, United States

Brooklyn, New York, United States

New York, New York, United States

New York, New York, United States

Richmond, Virginia, United States

Portland, Oregon, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Throughout study

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0